Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S3EM
|
|||
| Former ID |
DNCL003358
|
|||
| Drug Name |
CAZ AVI
|
|||
| Synonyms |
CAZ104
Click to Show/Hide
|
|||
| Indication | Serious infection [ICD-11: 1H0Z; ICD-10: A00-B99; ICD-9: 001-139] | Phase 3 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Beta-lactamase (Stap-coc blaZ) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01644643) Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens. U.S. National Institutes of Health. | |||
| REF 2 | NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.